Simple blood tests could spot liver cancer earlier in diabetics
NCT ID NCT07675187
First seen Jun 30, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This study investigates whether regular blood tests can detect liver cancer earlier in people with type 2 diabetes who also have significant liver scarring. Participants are randomly assigned to either a surveillance group receiving specialized blood tests every six months or a standard-care group. The goal is to see if the surveillance strategy leads to smaller tumors at diagnosis and better treatment outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GAAD score-based surveillance (blood tests for AFP, PIVKA-II, and liver function)
- What this could lead to
- If successful, this could establish a simple blood-test strategy to catch liver cancer earlier in people with type 2 diabetes, potentially improving treatment options and survival.
- What could go wrong
- This is a single-center trial in Taiwan, so results may not apply globally. The surveillance approach may not significantly improve detection or outcomes compared to standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can a new injection outperform semaglutide for diabetes remission?
- Can a drop of blood predict disease years before it strikes?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success